Escitalopram Impurity manufacturers
- MOMIPP
-
- $116.00
-
2026-07-27
- CAS:1363421-46-8
- Purity: 99.92%
- Supply Ability: 10g
|
| | Escitalopram Impurity Basic information |
| Product Name: | Escitalopram Impurity | | Synonyms: | (E)-3-(5-Methoxy-2-methyl-1H-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one;inhibit,Inhibitor,JNK1/2,BBB,Fab1,c-Jun,MOMIPP,Bcl-2,PIKfyve,Macropinocytosis,Bcl-xL;2-Propen-1-one, 3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-, (2E)-;Escitalopram Impurity;MOMIPP, 10 mM in DMSO;(2E)-3-(5-Methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one;MOMIPP | | CAS: | 1363421-46-8 | | MF: | C18H16N2O2 | | MW: | 292.33 | | EINECS: | | | Product Categories: | | | Mol File: | 1363421-46-8.mol |  |
| | Escitalopram Impurity Chemical Properties |
| Boiling point | 521.0±50.0 °C(Predicted) | | density | 1.239±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 31.25 mg/mL (106.90 mM; ultrasonic and warming and heat to 60°C) | | pka | 16.05±0.30(Predicted) | | form | Solid | | color | Yellow to orange |
| | Escitalopram Impurity Usage And Synthesis |
| Uses | MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB)[1][2]. | | in vivo | MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2]. | Animal Model: | Athymic CrTac:NCR-Foxn1 mice (female, 7-8weeks)[2] | | Dosage: | 80mg/kg
| | Administration: | i.p.; once daily; for 15 consecutive days | | Result: | Suppressed progression of intracerebral glioblastoma xenografts. |
| | References | [1] Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel). 2019 Mar 22;11(3):411. DOI:10.3390/cancers11030411
[2] Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19(1):77. DOI:10.1186/s12885-019-5288-y |
| | Escitalopram Impurity Preparation Products And Raw materials |
|